Published in Blood on October 01, 2012
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia (2013) 2.04
Natural killer cell biology: an update and future directions. J Allergy Clin Immunol (2013) 1.56
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia (2013) 1.52
Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol (2013) 1.29
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22
The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev (2014) 1.16
MHC-dependent inhibition of uterine NK cells impedes fetal growth and decidual vascular remodelling. Nat Commun (2014) 1.10
NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol (2014) 1.08
Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol (2014) 1.07
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol (2014) 1.04
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res (2015) 1.00
Immune checkpoint inhibitors in clinical trials. Chin J Cancer (2014) 0.98
CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res (2014) 0.96
Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer. Cancer J (2015) 0.94
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93
Immune Modulation in Hematologic Malignancies. Semin Oncol (2015) 0.92
Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res (2014) 0.92
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin (2015) 0.92
Ly49 receptors: innate and adaptive immune paradigms. Front Immunol (2014) 0.91
Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa. PLoS Med (2015) 0.90
Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica (2014) 0.89
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica (2014) 0.89
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Natural killer cells modulation in hematological malignancies. Front Immunol (2013) 0.88
Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Front Immunol (2015) 0.88
8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland. MAbs (2013) 0.88
Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron (2012) 0.87
Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One (2013) 0.86
Present and Future of Allogeneic Natural Killer Cell Therapy. Front Immunol (2015) 0.86
Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Front Immunol (2015) 0.85
Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy (2015) 0.84
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches. Front Immunol (2016) 0.84
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy (2015) 0.84
Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci (2016) 0.82
Monitoring NK cell activity in patients with hematological malignancies. Oncoimmunology (2013) 0.81
Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol (2013) 0.81
Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant (2015) 0.80
Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant (2016) 0.80
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells. J Transl Med (2016) 0.80
GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica (2015) 0.79
MicroRNA-29b mediates altered innate immune development in acute leukemia. J Clin Invest (2016) 0.78
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Front Immunol (2016) 0.78
The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses. Front Immunol (2013) 0.77
Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother (2013) 0.77
Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control. Front Immunol (2016) 0.77
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs (2014) 0.76
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. J Hematol Oncol (2016) 0.75
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Clin J Am Soc Nephrol (2016) 0.75
Salvage therapy of multiple myeloma: the new generation drugs. Biomed Res Int (2014) 0.75
Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise? Clin Cancer Res (2016) 0.75
Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol (2017) 0.75
Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy. Exp Mol Med (2017) 0.75
Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor. Front Immunol (2016) 0.75
Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. Immunotargets Ther (2015) 0.75
Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Front Immunol (2017) 0.75
Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig (2017) 0.75
Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev (2017) 0.75
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 7.40
Human natural killer cells. Blood (2008) 7.37
MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol (2005) 6.98
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res (2008) 5.50
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med (2006) 3.29
The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood (2010) 3.23
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 2.20
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol (2005) 1.99
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2004) 1.95
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother (2008) 1.95
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood (2006) 1.92
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood (2011) 1.41
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol (2005) 1.23
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood (2000) 1.21
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med (2004) 1.15
Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol (1990) 1.03
Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol (1996) 1.02
Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer (1984) 0.93
Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol (1992) 0.91
Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol (2011) 0.90
Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol (1997) 0.89
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. Int J Clin Lab Res (1997) 0.89
Immune dysfunction in multiple myeloma. Reduced natural killer cell activity and increased levels of soluble interleukin-2 receptors. APMIS (1991) 0.88
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leuk Lymphoma (2010) 0.84
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med (2007) 6.42
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol (2009) 5.73
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A (2012) 5.07
MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 4.91
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol (2008) 4.09
miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell (2010) 4.07
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell (2005) 3.44
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol (2002) 3.30
Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med (2006) 3.29
Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest (2006) 3.27
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Human natural killer cell development. Immunol Rev (2006) 3.14
A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity (2005) 3.14
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol (2008) 2.98
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol (2012) 2.94
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 2.86
In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood (2002) 2.85
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol (2009) 2.78
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
NK cell and DC interactions. Trends Immunol (2004) 2.68
Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity (2010) 2.67
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet (2005) 2.63
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity (2006) 2.56
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood (2011) 2.50
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet (2001) 2.46
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol (2005) 2.41
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 2.37
Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood (2007) 2.36
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
What does it take to make a natural killer? Nat Rev Immunol (2003) 2.30
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood (2003) 2.23
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 2.20
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood (2009) 2.18
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma (2012) 2.14
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood (2011) 2.11
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol (2007) 2.09
BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell (2003) 2.08
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res (2013) 2.02
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood (2014) 2.01
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell (2012) 2.01
Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol (2012) 1.98
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood (2009) 1.94
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood (2010) 1.89
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood (2006) 1.88
Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med (2006) 1.87
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol (2012) 1.85
Human natural killer cell development and biology. Blood Rev (2005) 1.83
Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products. J Biol Chem (2002) 1.80
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol (2012) 1.79
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet (2004) 1.79
Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev (2002) 1.77
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood (2012) 1.77
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica (2013) 1.76
Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci U S A (2004) 1.75